Literature DB >> 23550222

Dose Response of MTLn3 Cells to Serial Dilutions of Arsenic Trioxide and Ionizing Radiation.

Waseem Khan Raja1, Jahangir Satti, Gang Liu, James Castracane.   

Abstract

MTLn3 cells derived from mouse mammary epithelium are known to be highly malignant and are resistant to both radio- and chemo-therapy. We exposed MTLn3 cells to various doses of inorganic Arsenic trioxide (As2O3) in combination with ionizing radiation. Cells were treated with a series of As2O3 concentrations ranging from 20 μM to 1.22 nM for 8 hour, 24 hour and 48 hour periods. Post-treated cell proliferation was quantified by measuring mitochondrial activity and DNA analysis. Cells exposed to radiation and As2O3 at concentration greater than 1.25 μM showed apoptosis and radiations alone treated cells were statistically not different from the control. Hormesis was observed for As2O3 concentrations in the range of 0.078 μM to 0.625 μM while the combined chemo and radiation treatments of the cells did not affect the hormetic effect. We have demonstrated that As2O3 (in the presence and absence of ionizing radiation) in specific low concentrations induced apoptosis in the otherwise chemoresistant cancer cells. This low concentration-mediated cell death is immediately followed by a surge in cell survival. Low dosing dosimetry is highly desirable in metronomic therapy however, it has a narrow window since necrosis, hormesis, apoptosis and other dose-dependent biological processes take place in this region. Further quantifiable dosimetry is highly desired for routine clinical practice.

Entities:  

Keywords:  Apoptosis; Arsenic trioxide; Cancer cells; Hormesis; Ionizing radiation

Year:  2011        PMID: 23550222      PMCID: PMC3578452          DOI: 10.2203/dose-response.11-025.Raja

Source DB:  PubMed          Journal:  Dose Response        ISSN: 1559-3258            Impact factor:   2.658


  31 in total

1.  Radiation hormesis and radioadaptive response in Drosophila melanogaster flies with different genetic backgrounds: the role of cellular stress-resistance mechanisms.

Authors:  A A Moskalev; E N Plyusnina; M V Shaposhnikov
Journal:  Biogerontology       Date:  2011-01-14       Impact factor: 4.277

2.  Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis.

Authors:  Hui-Wen Chiu; Jing-Hua Lin; Yi-An Chen; Sheng-Yow Ho; Ying-Jan Wang
Journal:  Autophagy       Date:  2010-04-11       Impact factor: 16.016

3.  Multiple tumor marker elevation in androgen ablation-refractory prostate cancer with long-term response to metronomic chemotherapy: a case report.

Authors:  Mariangela Massaccesi; Franca Forni; Pasquale Spagnuolo; Gabriella Macchia; Samantha Mignogna; Maria De Ninno; Numa Cellini; Bruno Giardina; Arnaldo Carbone; Alessio G Morganti
Journal:  Int J Biol Markers       Date:  2010 Oct-Dec       Impact factor: 2.659

4.  Breast cancer occurred after Hodgkin's disease: clinico-pathological features, treatments and outcome: analysis of 214 cases.

Authors:  Bruno Cutuli; Samia Kanoun; Christine Tunon De Lara; Marc Baron; Lorenzo Livi; Cristelle Levy; Christine Cohen-Solal-Lenir; Anne Lesur; Pierre Kerbrat; Mariano Provencio; Laurence Gonzague-Casabianca; Alice Mege; Claire Lemanski; Catherine Delva; Sylvie Lancrenon; Michel Velten
Journal:  Crit Rev Oncol Hematol       Date:  2011-02-17       Impact factor: 6.312

5.  Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

Authors:  Urban Emmenegger; Giulio Francia; Annabelle Chow; Yuval Shaked; Andrew Kouri; Shan Man; Robert S Kerbel
Journal:  Neoplasia       Date:  2011-01       Impact factor: 5.715

Review 6.  Overview of resistance to systemic therapy in patients with breast cancer.

Authors:  Ana Maria Gonzalez-Angulo; Flavia Morales-Vasquez; Gabriel N Hortobagyi
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.

Authors:  Pawan Kumar; Qinghong Gao; Yu Ning; Zhuo Wang; Paul H Krebsbach; Peter J Polverini
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

8.  The emerging low-dose therapy for advanced cancers.

Authors:  Jahangir Satti
Journal:  Dose Response       Date:  2009-03-24       Impact factor: 2.658

9.  Direct speciation analysis of arsenic in sub-cellular compartments using micro-X-ray absorption spectroscopy.

Authors:  Thomas Bacquart; Guillaume Devès; Richard Ortega
Journal:  Environ Res       Date:  2009-10-02       Impact factor: 6.498

10.  Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.

Authors:  R Lord; S Nair; A Schache; J Spicer; Navita Somaihah; V Khoo; H Pandha
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

View more
  3 in total

1.  Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions.

Authors:  Iris R Bell; John A Ives; Wayne B Jonas
Journal:  Dose Response       Date:  2013-11-07       Impact factor: 2.658

2.  Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis.

Authors:  Erika B Dugo; Clement G Yedjou; Jacqueline J Stevens; Paul B Tchounwou
Journal:  Ann Clin Pathol       Date:  2017-01-04

3.  Dual effects of arsenic trioxide on tumor cells and the potential underlying mechanisms.

Authors:  Xiao Zhang; Dahai Yu; Huaize Geng; Fengmei Li; Lin Lv; Lei Zhao; Caichuan Yan; Baoxin Li
Journal:  Oncol Lett       Date:  2018-07-05       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.